Thermo Fischer Scientific Reports the Launch of the First-Ever GMP- and Cleanroom-Compatible CO2 Incubator

Thermo Fischer Scientific has launched a first-in-market CO2 incubator that combines optimal cell growth capabilities with certified cleanroom compatibility, effectively addressing the growing need among biotechnology, biopharmaceutical, and clinical laboratories for high-performance incubation systems that meet stringent cleanroom and cGMP standards.

Thermo Fischer Scientific Heracell Vios CR CO2 Incubator expands the Thermo Scientific Cell Therapy Systems (CTS) Series laboratory equipment portfolio with a solution specifically designed for use in GMP environments. Consistent with Thermo Fisher’s history of proven incubator technology, the new system provides optimal cell growth for even the most sensitive high-value cell cultures.

This new Vios CR CO2 incubator boasts fully enclosed casing and electronics, minimizing particle emissions in sync with critical particulate control in a Grade A/B cleanroom. Operating on the patented Thermo Scientific THRIVE active airflow technology, which delivers homogenous cell growth conditions and rapid parameter recovery in less than 10 minutes, the system prioritizes cell culture protection. Dependable contamination control is enabled through in-chamber HEPA filtration, on-demand 180°C sterilization, and an optional 100% pure copper interior chamber.

Featuring a robust stainless-steel exterior and IP54-compliant design, the Vios CR CO2 incubator can withstand the rigorous and repeated cleaning procedures that are integral to effective cleanroom management, enabling long-term use and maximum return on investment. The system is compatible with the STERIS Vaporized Hydrogen Peroxide (VHP) decontamination method, facilitating easy integration into existing sterilization workflows. Furthermore, the new incubator features independent TÜV SÜD certification for compatibility with ISO Class 5 cleanrooms, allowing scientists to confidently and effectively plan their cleanrooms to meet strict air quality requirements.

“As innovative research is being rapidly translated into promising therapies, we have seen dramatic growth in demand for premium incubators that are suitably equipped for use in controlled environments,” said Douglas Wernerspach, senior business director, Laboratory Products Division at Thermo Fisher Scientific. “To effectively meet this need, we have complemented the demonstrated recovery and uniformity capabilities of the Thermo Scientific Heracell VIOS CO2 Incubator and Thermo Scientific Forma Steri-Cycle CO2 incubators with exceptional cleanability and GMP-enabling features to deliver the first CO2 incubator that is specifically built for cleanroom use. This marks the latest step in our journey to better support cell therapy developers as they seek to bring innovative new therapeutics to patients.”

The new incubator comes with a range of cleanroom-compatible accessory options, including stacking adapters and roller bases to facilitate easy insertion into established laboratory processes. In addition, a comprehensive cGMP documentation package with recommended cleaning procedures and preventative maintenance protocols supports user-friendly, time-efficient implementation and validation.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”